Physician profile
Michael J Cruz
NPI 1083665145
$25,484.72
in general payments reported to CMS, 2019-2025
13 companies · $20K in 2025
The $20K reported for 2025 was more than what 98% of Plastic Surgery Within The Head & Neck providers received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $297 · 2021: $575 · 2022: $802 · 2023: $1,040 · 2024: $2,167 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $1,806 · Consulting Fee: $400 · Travel and Lodging: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,800.00 |
| Food and Beverage | $1,806.04 |
| Consulting Fee | $400.00 |
| Travel and Lodging | $178.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $21,666.14 | 2022-2025 | Nucala |
| Aerin Medical INC. | $895.95 | 2022-2024 | |
| Stryker Corporation | $779.60 | 2019-2023 | Scopis Ent |
| Regeneron Pharmaceuticals, INC. | $646.87 | 2021-2024 | Dupixent |
| Intersect Ent, INC. | $369.92 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $364.19 | 2019-2025 | |
| Genzyme Corporation | $361.88 | 2019-2025 | |
| Neurent Medical Limited | $98.97 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Arrinex, INC. | $78.46 | 2019 | |
| Medtronic, INC. | $74.20 | 2022 | |
| Medtronic USA, INC. | $68.04 | 2020 | |
| Optinose US, INC. | $52.98 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $27.52 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.